India's drug regulator has cleared toripalimab as a first-line immunotherapy for advanced esophageal squamous cell carcinoma, giving Dr Reddy's a second indication for the drug.
Dr Reddy's Laboratories has secured approval from the Drugs Controller General of India (DCGI) for Zytorvi (toripalimab) as a first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). The company announced the clearance on Wednesday, October 21.
The green light covers use alongside cisplatin and paclitaxel in adults whose disease is unresectable, advanced, recurrent or metastatic. It is Zytorvi's second approved indication in India, after nasopharyngeal carcinoma.
The scale of the problem is what makes this notable. The company says ESCC makes up roughly 80 per cent of esophageal cancer cases in India. Dr Reddy's says the approval is meant to widen access to first-line immunotherapy for these patients.
Zytorvi is a monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, helping T-cells attack cancer cells.
The approval rests on the Phase 3 JUPITER-06 trial. According to the company's release, adding toripalimab to paclitaxel and cisplatin cut the risk of disease progression or death by 42 per cent versus chemotherapy alone. In the final overall-survival analysis, median survival was 17.7 months with the combination against 12.9 months with chemotherapy alone.
For Dr Reddy's, the nod deepens its oncology push. It holds commercialisation rights for toripalimab in 21 countries under a 2023 agreement with China's Junshi Biosciences. Pricing and launch timelines were not part of the company's announcement.